A Phase I Randomized, Single-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 Following Single and Multiple Ascending Dose Administration in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Prospective, Non-interventional Cohort Study
Latest Information Update: 07 Apr 2026
At a glance
Most Recent Events
- 20 Mar 2026 Planned End Date changed from 30 Apr 2026 to 18 Jun 2026.
- 20 Mar 2026 Planned primary completion date changed from 30 Apr 2026 to 18 Jun 2026.
- 19 Dec 2025 Planned number of patients changed from 164 to 124.